Abacavir

🧮 Dose calculator

HIV-1 infection (treatment) · Regimen source: FDA Abacavir · 2.2

• • Always with other antiretrovirals (unless a complete regimen). FDA Abacavir · 2.2
• • Screen for HLA-B*5701 before starting. Mild hepatic impairment: 200 mg twice daily (oral solution). FDA Abacavir · 2.1FDA Abacavir · 2.4

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label: Antiretroviral Pregnancy Registry data show no difference from the background birth-defect rate. FDA Abacavir · 8.1

  “Available data from the APR show no difference in the overall risk of birth defects for abacavir compared with the background rate for birth defects of 2.7% in the Metropolitan Atlanta Congenital Defects Program (MACDP) reference population.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Abacavir · 8.2

  “Risk Summary The Centers for Disease Control and Prevention recommends that HIV-1-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Abacavir · 8.4

  “The safety and effectiveness of abacavir have been established in pediatric patients aged 3 months and older.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Abacavir · 8.5

  “In general, caution should be exercised in the administration of abacavir in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.